BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/24/2026 7:03:47 AM | Browse: 3 | Download: 0
 |
Received |
|
2025-10-27 07:35 |
|
Peer-Review Started |
|
2025-10-27 07:35 |
|
First Decision by Editorial Office Director |
|
2025-10-31 09:07 |
|
Return for Revision |
|
2025-10-31 09:07 |
|
Revised |
|
2025-11-14 09:19 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-21 02:38 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-21 07:28 |
|
Articles in Press |
|
2026-01-21 07:28 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-08 08:59 |
|
Publish the Manuscript Online |
|
2026-07-24 07:03 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Biochemistry & Molecular Biology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Evaluating cytokeratin 18 fragment as a non-invasive marker of fibrosis and lipid alterations in steatotic liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Noura A A Ebrahim, Soliman M A Soliman, Thoraya A Farghaly and Aya Mohamed Adel Arafat |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Noura A A Ebrahim, Department of Oncologic Pathology, National Cancer Institute, Cairo University, 1st Kasr-Alainy Street, Cairo 11796, Al Qāhirah, Egypt. npathologist@gmail.com |
| Key Words |
Cytokeratin 18 fragment; Steatotic liver disease; Metabolic dysfunction-associated steatotic liver disease; Hepatocyte apoptosis; FibroScan-aspartate aminotransferase score; Steatosis-Associated Fibrosis Estimator score; Non-invasive biomarkers; Lipid metabolism; Liver injury; Metabolic dysfunction |
| Core Tip |
Ichikawa et al examined the diagnostic utility of serum cytokeratin 18 fragment (CK18F) in patients with steatotic liver disease (SLD). Their findings demonstrated that CK18F-a marker of hepatocyte apoptosis-shows a strong relationship with liver injury markers and lipid disturbances, particularly elevated triglycerides, but not with conventional fibrosis indices. Notably, CK18F correlated closely with non-invasive composite scores such as FibroScan-aspartate aminotransferase and Steatosis-Associated Fibrosis Estimator, emphasizing its ability to reflect active hepatic inflammation and metabolic stress rather than fibrotic burden. These results suggest that incorporating CK18F into existing non-invasive assessment tools could enhance early detection and clinical stratification of individuals at metabolic and hepatic risk within the spectrum of metabolic dysfunction-associated SLD. |
| Publish Date |
2026-07-24 07:03 |
| Citation |
Ebrahim NAA, Soliman SMA, Farghaly TA, Arafat AMA. Letter to the Editor: Evaluating cytokeratin 18 fragment as a non-invasive marker of fibrosis and lipid alterations in steatotic liver disease. World J Hepatol 2026; 18(7): 115836
|
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i7/115836.htm |
| DOI |
https://doi.org/10.4254/wjh.115836 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
